This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, Crespo C, Stauble F, Rodríguez JM, Brosa M.Cost-effectiveness study of second line therapies in patients with idiopathic overactive bladder in Spain. 24th Annual Congress of the European Association of Urology: 136 abstr. 62, 18 Mar 2009
Leong RK, Weil EHJ, Van Kerrebroeck PEV.Cost-effectiveness analysis of sacral neuromodulation and botuline toxin A treatment for patients with overactive bladder. 24th Annual Congress of the European Association of Urology: 242 abstr. 488, 19 Mar 2009
Kessler TM, Khan S, Apostolidis A, Kalsi V, Panicker J, Roosen A, Elneil S, Fowler CJ, Dasgupta P.Sustained quality of life improvement after repeat intradetrusor injections of botulinum neurotoxin type a for refractory idiopathic detrusor overactivity. 24th Annual Congress of the European Association of Urology: 137 abstr. 67, 18 Mar 2009
Rights and permissions
About this article
Cite this article
SNM vs botulinum toxin A in OAB: cost effectiveness debated. Pharmacoecon. Outcomes News 578, 8 (2009). https://doi.org/10.2165/00151234-200905780-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905780-00016